补中益气汤联合分子靶向药物治疗肺腺癌的临床研究  

Clinical Research on Treating NSCLC in Center-Supplementing and Qi-Boosting Decoction plus Molecular Targeted Medicine

作　　者：王晓开[1] 周琳[1] 刘春英[1] 

机构地区：[1]辽宁中医药大学,辽宁沈阳110032

出　　处：《辽宁中医杂志》2017年第6期1256-1258,共3页Liaoning Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金(81473569)

摘　　要：目的:观察补中益气汤联合分子靶向药物治疗肺腺癌的临床效果。方法:将符合实验条件的40例患者根据治疗方法不同随机分为两组:实验组(补中益气汤联合分子靶向药物治疗);对照组(单用分子靶向药物治疗)。治疗直至肿瘤进展或不良反应不能耐受为止,观察两组的治疗效果,耐药基因T790M突变的时间,临床症状及不良反应。结果:不同方法治疗后对照组的有效率和疾病控制率分别为65.00%、80.00%,实验组为70.00%、95.00%,两组比较无显著差异(P>0.05)。与对照组比较,实验组T790M基因突变的平均时间长(P<0.05),基因突变携带者人数减少,不良反应发生率无显著差异(P>0.05)。结论:补中益气汤联合分子靶向药物治疗肺腺癌可影响肺腺癌细胞耐药,临床值得推广应用。Objective ： To observe the repair of Center - Supplementing and Qi - Boosting Decoction combined molecular targe- ted drugs for treatment of lung adenocarcinoma. Methods ： Forty patients diagnosed as lung adenocarcinoma of the were randomly divided into two groups. The observation group used Center - Supplementing and Qi - Boosting Decoction combined Geftinat while the control group used Geftinat alone. Treat until tumor progression or adverse reactions cannot tolerate. Observe the therapeutic effect of two groups, clinical symptoms and adverse reactions, drug resistance gene T790M mutation. Results：The clinical effective rate （RR） in the control group and observation group were 65.00% and 70.00% respectively and the disease control rates （DCR） in the control group and observation group were 80.00% and 95.00% respectively. There was no significant difference （P 〉0. 05 ）. The incidence of adverse reactions（ skin rashes and mild diarrhea） had no significant difference （P 〉0. 05 ）. Aver- age time of drug - resistant genes T790M mutationin the control group and observation group was 10.5 months and 14.0 months, with significant differences （ P 〈 0. 05 ）. Conclusion ： Center - Supplementing and Qi - Boosting Decoction plus molecular targeted medicine can influence the NSCLC,which deserves generalization and application clinic.

关 键 词：肺腺癌 免疫组化 补中益气汤 分子靶向药 

分 类 号：R734.2[医药卫生—肿瘤]